PTO/SB/08s (06-03.)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Figures Appear

Under the Paperwork Reduction Act of 1995, no persons are required to re to a collection of information unless it contains a valid OMB control number. Application Number

Filing Date

INCODMATION DISCLOSURE

OTATEMENT DV ADDI IOANT					First Named Inventor Thomas BUELOW							
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)				Art Unit								
(NOTION SUBMISSION UNDER 37 GFR 1.55)				Exami	Examiner Name			•				
				Attorn	Attorney Docket Number PHDE030407US			s	3			
	U.S.PATENTS Remove											
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ssue Date Name of Patentee or Applicant			Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	5239591		1993-08	3-24	Ranganath		all	all			
	2	6047080		2000-04	1-04	Chen, et a	ıl.		all			
	3	6501848	B1	2002-12	2-31	Carroll, et	al.		all			
	4	6754376	B1	2004-06	3-22	Turek, et a	3ł.		all			
If you wish to add additional U.S. Patent citation information please click the Add button.												
	U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code ¹			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	20050008210	A1	2005-01-13 E		Evron, et al.		all				
If you wish to add additional U.S. Published Application citation information please click the Add button. Add												
				FOREIG	SN PAT	ENT DOC	UM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³			Kind Code4	Publication Date Name of Patentee Applicant of cited Document		e or	where Rel	umns,Lines evant or Relevan	Ts	

Application Number | Filing Date | Filing Date | Filing Date | Filing Manual Inventor | Filing Date | Filing Manual Inventor | Filing Manual Inven

	1	wo:	2004/06841	wo	A1	2004-08-12	KPENV	all	
If you wis	h to a	dd add	fitional Foreign F	atent Document	citation	information pl	ease click the Add butto	n Add	_
				NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Ţs	
	GUPTA, A, et al.; Cardiac MR Image Segmentation Using Deformable Models; 1993; IEEE Proc. of the Computers in Cardiology Conference; pp. 747-750.								
	2 CORNELIS, J., et al., Techniques for Cardiac Image Segmentation, 1992, IEEE Proc. of the Inft. Conf. of the Engineering in Medicine and Biology Soc.; 5(14)1906-1908.								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner	Sign	ature					Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Mot Codes of USPTO Patent Documents at swee, ISPTO_DQLy or MEPF 96104. * Enter office that issued the document, by the two-letter code (WIPO Standard ST.3.) * For Lapranese plant for comments, the solicitation of the year of the register or the process of the serial number of the plant for comment by the appropriate symbols as exclusived on the document under WIPO Standard ST.1.6 if possible. * Applicant is to place a check mark their if English Insignages resistation is situated.*

Application Number Fling Date Flang Date Fla

CERTIFICATION STATEMENT

Please see	37 CFR	1 97 ar	nd 1 98 to	make the	appropriate	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.39(file).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/TML/	Date (YYYY-MM-DD)	2006-05-31
Name/Print	Thomas M. Lundin	Registration Number	48979

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.